Bellerophon Therapeutics, Inc.

BLPH · NASDAQ
Analyze with AI
9/30/2023
6/30/2023
3/31/2023
12/31/2022
Assets
Cash & Equivalents$4,382$10,575$15,172$6,924
Short-Term Investments$0$0$0$405
Receivables$0$0$0$0
Inventory$0$0$0$0
Other Curr. Assets$597$670$599$234
Total Curr. Assets$4,979$11,245$15,771$7,563
Property Plant & Equip (Net)$0$0$9$186
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$0$0$0$0
Tax Assets$0$0$0$0
Other NC Assets$0$0$186$186
Total NC Assets$0$0$195$372
Other Assets$0$0$0$0
Total Assets$4,979$11,245$15,966$7,935
Liabilities
Payables$612$1,887$1,070$1,230
Short-Term Debt$0$0$16$203
Tax Payable$0$0$0$0
Deferred Revenue$0$0$0$0
Other Curr. Liab.$644$3,735$4,278$3,968
Total Curr. Liab.$1,256$5,622$5,364$5,401
LT Debt$0$0$0$0
Deferred Rev, NC$0$0$0$0
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$0$0$0$0
Total NC Liab.$0$0$4,286$0
Other Liabilities$0$0-$4,286$0
Cap. Leases$0$0$8$203
Total Liabilities$1,256$5,622$5,364$5,401
Equity
Pref Stock$0$0$0$0
Common Stock$122$122$104$96
Retained Earnings-$256,315-$254,394-$249,256-$252,078
AOCI$0$0$0$0
Other Equity$259,916$259,895$259,754$254,516
Total Equity$3,723$5,623$10,602$2,534
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$4,979$11,245$15,966$7,935
Net Debt-$4,382-$10,575-$15,156-$6,721